HTLV-I/II seropositivity and death from AIDS among HIV-1 seropositive intravenous drug users

J. B. Page, S. Lai, D. D. Chitwood, N. G. Klimas, P. C. Smith, Mary Ann Fletcher

Research output: Contribution to journalArticle

91 Scopus citations

Abstract

In a prospective study of street-recruited intravenous drug users (IVDUs) in Miami, Florida, USA, 107 (46·5%) of 230 IVDUs were infected with HIV-1. Of these HIV-1 seropositive individuals, 23 were also infected with human T-lymphotropic virus type I or II (HTLV-I/II). To test the hypothesis that HTLV-I/II infection has an effect on the survival of HIV-1 seropositive IVDUs, various baseline clinical and laboratory HIV-1 related indices in HTLV-I/II positive and negative groups were compared. Life table analysis and Cox's proportional hazards model were used to estimate the potential effect of HTLV-I/II infection on the survival patterns of people infected with HIV-1. IVDUs infected with both viruses were three times more likely to die from AIDS during follow-up than were those infected with HIV-1 only. This finding suggests that HTLV-I/II seropositivity may adversely affect the clinical outcome of HIV-1 seropositive patients.

Original languageEnglish (US)
Pages (from-to)1439-1441
Number of pages3
JournalThe Lancet
Volume335
Issue number8703
DOIs
StatePublished - Jun 16 1990

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'HTLV-I/II seropositivity and death from AIDS among HIV-1 seropositive intravenous drug users'. Together they form a unique fingerprint.

  • Cite this

    Page, J. B., Lai, S., Chitwood, D. D., Klimas, N. G., Smith, P. C., & Fletcher, M. A. (1990). HTLV-I/II seropositivity and death from AIDS among HIV-1 seropositive intravenous drug users. The Lancet, 335(8703), 1439-1441. https://doi.org/10.1016/0140-6736(90)91456-K